{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:29:51Z","timestamp":1793424591997,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.beem.2023.101788","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T12:12:10Z","timestamp":1685967130000},"page":"101788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks"],"prefix":"10.1016","volume":"37","author":[{"given":"Charlotte","family":"H\u00f6ybye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib1","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/EJE-18-0306","article-title":"Therapy of endocrine disease: growth hormone replacement therapy in adults: 30 years of personal clinical experience","volume":"179","author":"J\u00f8rgensen","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.beem.2023.101788_bib2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1210\/jcem-18-8-901","article-title":"Treatment of a pituitary dwarf with human growth hormone","volume":"18","author":"Raben","year":"1958","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101788_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1651-2227.1987.tb17090.x","article-title":"Production of authentic recombinant somatropin","volume":"331","author":"Fryklund","year":"1987","journal-title":"Acta Paediatr Scand Suppl"},{"key":"10.1016\/j.beem.2023.101788_bib4","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(89)92328-3","article-title":"Beneficial effects of growth hormone treatment in GHdeficient adults","volume":"1","author":"Jorgensen","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2023.101788_bib5","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM198912283212605","article-title":"The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency","volume":"321","author":"Salomon","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2023.101788_bib6","first-page":"148","article-title":"Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children","volume":"104","author":"Kastrup","year":"1983","journal-title":"Acta Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2023.101788_bib7","article-title":"Usefulness and potential pitfalls of long-acting growth hormone analogs","volume":"24","author":"Yuen","year":"2021","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101788_bib8","first-page":"717","article-title":"Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human","volume":"19","author":"Giustina","year":"1998","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ecl.2006.11.005","article-title":"Effects of growth hormone on glucose and fat metabolism in human subjects","volume":"36","author":"J\u00f8rgensen","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.beem.2023.101788_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101316","article-title":"Treatment of the adult growth hormone deficiency syndrome with growth hormone: what are the implications for other hormone replacement therapies for hypopituitarism?","volume":"52","author":"Fierro","year":"2020","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"10.1016\/j.beem.2023.101788_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecl.2012.04.009","article-title":"Insulin-like growth factor physiology: what we have learned from human studies","volume":"41","author":"Holly","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"11","key":"10.1016\/j.beem.2023.101788_bib12","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41388-020-1154-2","article-title":"IGFBP2: integrative hub of developmental and oncogenic signaling network","volume":"39","author":"Li","year":"2020","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.beem.2023.101788_bib13","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.3390\/ijms23084358","article-title":"IGFBP-6: at the crossroads of immunity, tissue repair and fibrosis","volume":"23","author":"Liso","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.beem.2023.101788_bib14","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1530\/EC-18-0047","article-title":"Growth Hormone Research Society. Growth Hormone Research Society perspective on biomarkers of GH action in children and adults","volume":"7","author":"Johannsson","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1530\/eje.1.02191","article-title":"Incidence of GH deficiency - a nationwide study","volume":"155","author":"Stochholm","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101788_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-2265.2001.01406.x","article-title":"Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain","volume":"55","author":"Regal","year":"2001","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101788_bib17","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2023.101788_bib18","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4158\/GL-2019-0405","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of Growth Hormone Deficiency in adults and in patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocr Pr"},{"issue":"5","key":"10.1016\/j.beem.2023.101788_bib19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1530\/EC-18-0096","article-title":"The prevalence of the metabolic syndrome and associated cardiovascular complications in adult-onset GHD during GH replacement: a KIMS analysis","volume":"7","author":"Verhelst","year":"2018","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1210\/jc.2009-1326","article-title":"International Hypopituitary Control Complications Study Advisory Board. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement","volume":"95","author":"Attanasio","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1210\/jcem-70-1-207","article-title":"Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites","volume":"70","author":"J\u00f8rgensen","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2023.101788_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/BF03349206","article-title":"Long-term GH treatment of GH-deficient adults: comparison between one and two daily injections","volume":"29","author":"H\u00f6ybye","year":"2006","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.beem.2023.101788_bib23","first-page":"1222","article-title":"Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults","volume":"86","author":"Laursen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101788_bib24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ghir.2015.12.002","article-title":"Variability in adherence to rhGH treatment: Socioeconomic causes and effect on children's growth","volume":"26","author":"De Pedro","year":"2016","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.beem.2023.101788_bib25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13030","article-title":"Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood?","volume":"84","author":"Auer","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101788_bib26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13030","volume":"84","author":"Rosenfeld","year":"2016","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2023.101788_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278293","article-title":"Experience of switching from a daily to a less frequent administration of injection treatments","volume":"17","author":"Loftus","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.beem.2023.101788_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-17-1073","article-title":"REAL 2 Study Group. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101788_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.980979","article-title":"What do we do now that the long-acting growth hormone is here?","volume":"13","author":"Miller","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2023.101788_bib30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-09-0422","article-title":"Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH","volume":"161","author":"Touraine","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2023.101788_bib31","first-page":"715","article-title":"A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency","volume":"Supplement 2","author":"Silverman","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101788_bib32","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1210\/jc.2013-2502","article-title":"24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency","volume":"99","author":"Khadilkar","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2023.101788_bib33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1210\/jc.2015-3279","article-title":"A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency","volume":"101","author":"Moore","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2023.101788_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102421","article-title":"Efficacy and safety of long-acting growth hormone in adult growth hormone deficiency: a systematic review and meta-analysis","volume":"16","author":"Dutta","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.beem.2023.101788_bib35","doi-asserted-by":"crossref","first-page":"1040046","DOI":"10.3389\/fendo.2022.1040046","article-title":"Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation","volume":"13","author":"Bidlingmaier","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2023.101788_bib36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1210\/clinem\/dgaa775","article-title":"Optimal monitoring of weekly IGF-I levels during growth hormone therapy with once-weekly somapacitan","volume":"106","author":"Juul Kildemoes","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib37","doi-asserted-by":"crossref","first-page":"bvab168","DOI":"10.1210\/jendso\/bvab168","article-title":"Average IGF-1 prediction for once-weekly lonapegsomatropin in children with growth hormone deficiency","volume":"6","author":"Lin","year":"2021","journal-title":"J Endocr Soc"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/EJE-21-1167","article-title":"Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency","volume":"187","author":"Kildemoes","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib39","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/EJE-11-0558","article-title":"Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis","volume":"166","author":"Hazem","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2023.101788_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/EJE-12-1083","article-title":"Fifteen years of GH replacement improves body composition and cardiovascular risk factors","volume":"168","author":"Elbornsson","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib41","first-page":"279","article-title":"Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency","volume":"84","author":"Janssen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jc.2013-2394","article-title":"Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH-an update","volume":"99","author":"Gazzaruso","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2023.101788_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ghir.2011.01.001","article-title":"Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency","volume":"21","author":"J\u00f8rgensen","year":"2011","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.beem.2023.101788_bib44","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations-current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2023.101788_bib45","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1046\/j.1365-2265.1998.00460.x","article-title":"Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults","volume":"48","author":"al-Shoumer","year":"1998","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2023.101788_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12020-017-1492-1","article-title":"Treatment of adult growth hormone deficiency with human recombinant growth hormone: an update on current evidence and critical review of advantages and pitfalls","volume":"60","author":"Ramos-Lev\u00ed","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2023.101788_bib47","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/cen.13502","article-title":"Long-term safety of growth hormone-A combined registry analysis","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101788_bib48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ghir.2015.06.006","article-title":"Reviewing the safety of GH replacement therapy in adults","volume":"25","author":"Stochholm","year":"2015","journal-title":"Growth Horm IGF Res"},{"issue":"2","key":"10.1016\/j.beem.2023.101788_bib49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cen.13256","article-title":"The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real-life data from the NordiNet\u00ae International Outcome Study","volume":"86","author":"Weber","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib50","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12902-019-0464-2","article-title":"No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope\u00ae): data from an observational, longitudinal study","volume":"19","author":"Beck-Peccoz","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"12","key":"10.1016\/j.beem.2023.101788_bib51","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14740338.2020.1839410","article-title":"Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs","volume":"19","author":"H\u00f6ybye","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.beem.2023.101788_bib52","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1210\/jc.2005-0928","article-title":"Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency","volume":"90","author":"Hoffman","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2023.101788_bib53","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1210\/jc.2010-2819","article-title":"Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency","volume":"96","author":"Biller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2023.101788_bib54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11102-012-0422-8","article-title":"12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency","volume":"16","author":"Biller","year":"2013","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.beem.2023.101788_bib55","doi-asserted-by":"crossref","first-page":"e1358","DOI":"10.1210\/clinem\/dgaa049","article-title":"Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial","volume":"105","author":"Johannsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.beem.2023.101788_bib56","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-17-1073","article-title":"REAL 2 Study Group. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2023.101788_bib57","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/cen.14273","article-title":"Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone","volume":"93","author":"Otsuka","year":"2020","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2023.101788_bib58","article-title":"Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency","author":"Takahashi","year":"2022","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.beem.2023.101788_bib59","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1530\/EJE-12-0484","article-title":"Effects on insulin sensitivity and body composition of combination therapy with GH and IGF1 in GH deficient adults with type 2 diabetes","volume":"167","author":"Barner","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.beem.2023.101788_bib60","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1002\/cam4.871","article-title":"Is there a role for IGF-1 in the development of second primary cancers?","volume":"5","author":"Shanmugalingam","year":"2016","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","article-title":"Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis","volume":"15","author":"Roelfsema","year":"2012","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.beem.2023.101788_bib63","doi-asserted-by":"crossref","first-page":"P35","DOI":"10.1530\/EJE-21-1186","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2023.101788_bib64","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2265.2011.04137.x","article-title":"Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency","volume":"75","author":"Schneider","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2023.101788_bib65","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0267","article-title":"Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies","volume":"12","author":"H\u00f6ybye","year":"2022","journal-title":"Endocr Connect"},{"key":"10.1016\/j.beem.2023.101788_bib66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/039463200401700105","article-title":"Growth hormone antibodies formation in patients treated with recombinant human growth hormone","volume":"17","author":"Ahangari","year":"2004","journal-title":"Int J Immunopathol Pharm"},{"key":"10.1016\/j.beem.2023.101788_bib67","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000497409","article-title":"Biological significance of anti-GH antibodies in children treated with rhGH","volume":"91","author":"Binder","year":"2019","journal-title":"Horm Res Paediatr"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X23000623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:00:27Z","timestamp":1761498027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X23000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521690X23000623"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2023.101788","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2023.101788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101788"}}